Daphne Haas-Kogan | |
---|---|
Born | Israel | March 26, 1964
Academic background | |
Education | BSc, Biochemistry and Molecular Biology, 1986, Harvard University MD, UCSF School of Medicine |
Academic work | |
Institutions | Harvard Medical School University of California,San Francisco |
Daphne Adele Haas-Kogan (born March 26,1964) is an American radiation oncologist. She is the Willem and Corrie Hees Family Professor of Radiation Oncology at Harvard Medical School.
Haas-Kogan was born on March 26,1964. [1] She was born to father Martin Haas,a Holocaust survivor from the south of the Netherlands. Following the Holocaust,he relocated to Israel then brought his family to San Diego in 1980. [2]
Following high school,Haas-Kogan completed her undergraduate degree in biochemistry and molecular biology from Harvard University and her medical degree from the University of California,San Francisco (UCSF). She remained at UCSF for her radiation oncology residency,where she was also the chief resident and a postdoctoral fellow. [3]
In July 2015,Haas-Kogan succeeded Jay Harris as Chair of the Department of Radiation Oncology at the Dana–Farber Cancer Institute,Brigham and Women’s Hospital (BWHC),and Boston Children’s Hospital. She was also appointed professor at Harvard Medical School and become an endowed professor of Radiation Oncology at BWHC. [3] Two years later,Haas-Kogan was installed as the Radiation Oncology Professor at Harvard Medical School [4] and elected a fellow of the Association of American Physicians. [5]
In 2019,Haas-Kogan was elected a member of the National Academy of Medicine "for research on the study of genetic abnormalities of brain tumors and successfully translating laboratory discoveries to the treatment of cancer,which led to a multitude of successful clinical trials that have helped shape targeted therapies for adult and pediatric malignancies." [6] She was also honored with an election to the American Society for Radiation Oncology Fellow designation. [7] In January 2020,Haas-Kogan was named to Boston magazine's 2020 Top Doctors. [8] During the same month,she received a research grant for her project "Dependence of DIPGs on DNA polymerase q for DNA repair defines a new therapeutic target." [9]
Haas-Kogan and her partner Suzanne Ezrre have three children together. [10]
Harvard Medical School (HMS) is the medical school of Harvard University and is located in the Longwood Medical Area in Boston,Massachusetts. Founded in 1782,HMS is one of the oldest medical schools in the United States,and provides patient care,medical education,and research training through its 15 clinical affiliates and research institutes,including Massachusetts General Hospital (MGH),Boston Children's Hospital,Dana–Farber Cancer Institute,Brigham and Women's Hospital,Beth Israel Deaconess Medical Center,Mount Auburn Hospital,McLean Hospital,Cambridge Health Alliance,The Baker Center for Children and Families,Spaulding Rehabilitation Hospital,and others
Massachusetts General Hospital is a teaching hospital located in the West End neighborhood of Boston,Massachusetts. It is the original and largest clinical education and research facility of Harvard Medical School/Harvard University,and houses the world's largest hospital-based research program with an annual research budget of more than $1.2 billion in 2021. It is the third-oldest general hospital in the United States with a patient capacity of 999 beds. Along with Brigham and Women's Hospital,Mass General is a founding member of Mass General Brigham,formerly known as Partners HealthCare,the largest healthcare provider in Massachusetts.
Sidney Farber was an American pediatric pathologist. He is regarded as the father of modern chemotherapy for his work using folic acid antagonists to combat leukemia,which led to the development of other chemotherapeutic agents against other malignancies. Farber was also active in cancer research advocacy and fundraising,most notably through his establishment of the Jimmy Fund,a foundation dedicated to pediatric research in childhood cancers. The Dana–Farber Cancer Institute is named after him.
Dana-Farber Cancer Institute (DFCI) is a comprehensive cancer treatment and research center in Boston,Massachusetts. Dana-Farber is the founding member of the Dana-Farber/Harvard Cancer Center,Harvard's Comprehensive Cancer Center designated by the National Cancer Institute,and one of the 15 clinical affiliates and research institutes of Harvard Medical School.
Laurie Hollis Glimcher is an American physician-scientist who was appointed president and CEO of Dana–Farber Cancer Institute in October 2016. She was elected a member of the American Philosophical Society in 2019. Glimcher has been at the center of controversies related to animal rights activists,excessive corporate payments,and research misconduct. A 2021 investigation by the Boston Globe Spotlight team highlighted Glimcher’s activities on multiple corporate boards,including Bristol Myers Squibb,GlaxoSmithKline,and Analog Devices. After this investigation,Glimcher continued to receive compensation on for-profit boards,while doubling her salary to $4 million per year at Dana-Farber.
Global Oncology (GO) is an American 501(c)(3) community-based global health organization. The organization was initially established at Harvard University in 2012 and now operates out of the Bay Area.
Eric P. Winer is a medical oncologist and clinical researcher specializing in breast cancer. He is director of Yale Cancer Center and president and physician-in-chief of Smilow Cancer Hospital Yale New Haven Health System,effective February 1,2022. He also is Deputy Dean for Cancer Research at Yale School of Medicine. From 1997 to 2021,he was the Chief of the Breast Oncology Program at Dana–Farber Cancer Institute in Boston,Massachusetts. Beginning in 2013,he held a range of institutional roles at Dana-Farber,including Chief of Clinical Development,the Thompson Chair in Breast Cancer Research and Director of the Dana-Farber/Harvard SPORE in Breast Cancer. He also served as a Professor of Medicine at Harvard Medical School. He was president of the American Society of Clinical Oncology (ASCO) 2022-2023 and became Chair of the Board in mid-June 2023. His career has been focused on breast cancer treatment and research.
Carolyn Kaelin was an American cancer surgeon. She worked at the Dana–Farber Cancer Institute and founded the Comprehensive Breast Health Center at Brigham and Women’s Hospital in 1995.
Mary-Ellen Taplin,is a research oncologist at Dana Farber Cancer Institute and Brigham and Women's Hospital in Harvard's Longwood Medical and Academic Area.
Jay Steven Loeffler was an American physician at Massachusetts General Hospital,where he served as chair of the Department of Radiation Oncology since 2000. He was the Herman and Joan Suit Professor of Radiation Oncology and professor of neurosurgery at Harvard Medical School.
Judy Ellen Garber is the director of the Center for Cancer Genetics and Prevention at the Dana–Farber Cancer Institute and a professor of medicine at Harvard Medical School. Garber previously served as president of the American Association for Cancer Research.
Michelle Leigh Monje-Deisseroth is a neuroscientist and neuro-oncologist. She is a professor of neurology at Stanford University and an investigator with the Howard Hughes Medical Institute. She develops new treatments for diffuse intrinsic pontine glioma.
Nancy Jane Tarbell is the C.C. Wang Professor of Radiation Oncology at Harvard Medical School and Massachusetts General Hospital. Previously,she was the Dean for Academic and Clinical Affairs at Harvard Medical School (2008–2019).
Larissa Nekhlyudov is an American general internist. She is a professor of medicine at Harvard Medical School,primary care physician at the Brigham and Women’s Hospital and Clinical Director of Internal Medicine for Cancer Survivors at the Dana–Farber Cancer Institute.
Ann Hart Partridge is an American medical oncologist. She is the founder and director of the Young and Strong Program for Young Women with Breast Cancer at the Susan F. Smith Center for Women's Cancers at the Dana–Farber Cancer Institute.
Catherine J. Wu is an American physician-scientist who studies oncology. She is a Professor of Medicine and Chief of Division of Stem Cell Transplantation and Cellular Therapies at the Dana–Farber Cancer Institute. Her research focuses on longitudinal studies of patients with chronic lymphocytic leukemia (CLL).
Monica Bertagnolli is an American surgical oncologist and the 17th director of the National Institutes of Health. She previously served as the 16th director of the National Cancer Institute (NCI). Prior to her governmental positions,she worked at Brigham and Women's Hospital and Dana–Farber Cancer Institute and was the Richard E. Wilson Professor of Surgery at Harvard Medical School.
Benjamin Levine Ebert is the Chair of Medical Oncology at the Dana–Farber Cancer Institute and the George P. Canellos,MD and Jean S. Canellos Professor of Medicine at Harvard Medical School. Ebert is the president-elect and CEO of Dana-Farber effective October 1,2024 succeeding Laurie Glimcher.
Nancy Lin is an American oncologist who works at the Dana-Farber Cancer Institute and is an Associate Professor of Medicine at Harvard Medical School. Her research considers new diagnostic strategies and treatment pathways for HER2 positive breast cancer.
James D. Griffin is an American physician-scientist. He is currently Professor of Medicine at Harvard Medical School,Chair of Medical Oncology at Dana–Farber Cancer Institute,and Director of Medical Oncology at Brigham and Women's Hospital. He is considered an expert in medical oncology and is widely recognized for his research in the clinical and biologic aspects of hemotologic malignancies.